Tetraline, phenylcyclobutane and phenylcyclopentane analogs as rxfp1 agonists

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is halo, C1-4 alkyl substituted with 0-5 halo, ═O, OH, or —OC1-4 alkyl substituted with 0-5 halo;
• R2 is halo, CN, C1-4 alkyl substituted with 0-5 halo or OH, or —OC1-4 alkyl substituted with 0-5 halo, OH, or —OC1-4 alkyl;
• R3 is C1-4 alkyl substituted with 0-5 R4, —(CRdRd)n, —C3-10-carbocyclyl substituted with 0-5 R4 or —(CRdRd)n-3 to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, N, and NRd, and substituted with 0-5 R4;
• R4 is halo, CN, C1-4 alkyl substituted with 0-5 halo, OH, —OC1-4 alkyl substituted with 0-5 halo, —S(O)pRc, aryl, or a 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, N, and NRd;
• R5 is C3-6 carbocyclyl substituted with 0-3 R5 and 0-2 R7, or a 3- to 12-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, N and NR10 substituted with 0-3 R5 and 0-1 R7;
• wherein said heterocyclyl is bonded to the phenyl moiety through a carbon or nitrogen atom;
• R6 is halo, CN, ═O, —OH, —OC1-4 alkyl, or C1-4 alkyl substituted with 0-2 halo or OH;
• R7 is C1-4 alkyl substituted with 0-1 R8 and 0-1 R9, —OR, —NRaRa, —NRaC(═O)Rb, —NRaC(═O)ORb, —NRaC(═O)NRaRa, —NRaS(═O)pRc, —C(═O)Rb, —C(═O)ORb, —C(═O)NRaRa, —C(═O)NRaS(═O)pRc, —OC(═O)Rb, —S(═O)pRc, —S(═O)pNRaRa, C3-6 cycloalkyl, or a 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, N and NRd, and substituted with 0-5 Rc;
• R8 is halo, —C(═O)ORb, —C(═O)NRaRa, —C(═O)NRaORb, or C1-4 alkyl substituted with 0-3 halo or OH;
• R9 is —ORb, —NRaRa, —NRaC(═O)Rb, —NRaC(═O)ORb, —NRaC(═O)NRaRa, —NRaS(═O)pRc, —NRaS(O)pNRaRa, —OC(═O)NRaRa, —OC(═O)NRaORb, —S(═O)pNRaRa, —S(O)pRc, —(CH2)n—C3-6 carbocyclyl substituted with 0-3 Re, or —(CH2)n-heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, and N, and substituted with 0-3 Re;
• R10 is H, C1-4 alkyl substituted with 0-2 R11, —C(═O)Rb, —C(═O)ORb, —C(═O)NRaRa, C3-6 cycloalkyl substituted with 0-5 Re, or a 4- to 6-membered heterocyclyl comprising 1-4 heteroatoms selected from O, S(═O)p, N and NR12, and substituted with 0-5 Re;
• R11 is —OH, —C(═O)OH, or aryl;
• R12 is H, C1-3 alkyl, or aryl;
• Ra is H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10 carbocyclyl substituted with 0-5 Re, or —(CH2)u-heterocyclyl substituted with 0-5 Re;
• or Ra and Ra together with the nitrogen atom to which they are both attached form a heterocyclyl substituted with 0-5 Re;
• Rb is H, C1-6 alkyl substituted with 0-5 Re, C2-6 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, —(CH2)n—C3-10 carbocyclyl substituted with 0-5 Re, or —(CH2)n-heterocyclyl substituted with 0-5 Re;
• Rc is C1-6 alkyl substituted with 0-5 Re, C2-4 alkenyl substituted with 0-5 Re, C2-6 alkynyl substituted with 0-5 Re, C1-6 carbocyclyl, or heterocyclyl;
• Rd is H or C1-4 alkyl;
• Re is halo, CN, NO2, ═O, C1-6 alkyl substituted with 0-5 Rg, C2-6 alkenyl substituted with 0-5 Rg, C2-6 alkynyl substituted with 0-5 Rg, —(CH2)n—C3-6 cycloalkyl, —(CH2)n-aryl, —(CH2)n-heterocyclyl, —(CH2)nORf, —C(═O)ORf, —C(═O)NRfRf, —NRfC(═O)Rf, —S(═O)pRf, —S(═O)pNRfRf, —NRfS(═O)pRf, —NRfC(═O)ORf, —OC(═O)NRfRf, or —(CH2)nNRfRf;
• Rf is H, C1-6 alkyl, C3-6 cycloalkyl, aryl, or heterocyclyl;
• or Rf and Rf together with the nitrogen atom to which they are both attached form a heterocyclyl;
• Rg is halo, CN, OH, C1-6 alkyl, C3-6 cycloalkyl, or aryl;
• n is zero, 1, 2, or 3;
• and
• p is zero, 1, or 2.